What are the alternatives if Suboxone (buprenorphine/naloxone) is unavailable for a heroin‑dependent adult who declines a formal treatment program?

Alternative Medications When Suboxone Is Unavailable

If Suboxone (buprenorphine/naloxone) is unavailable, methadone is the preferred alternative for heroin-dependent adults, with the strongest evidence for effectiveness and highest treatment retention rates. 1, 2, 3

First-Line Alternatives in Order of Preference

1. Methadone (Strongest Alternative)

• Most robust evidence base for opioid use disorder treatment 2
• Higher treatment retention rates compared to buprenorphine 3
• Can be administered for up to 72 hours without participation in an opioid treatment program 1
• Particularly indicated for:
  • Injection drug users (higher dropout risk) 3
  • Patients with persistent withdrawal symptoms or cravings
  • Socially unstable patients at high risk of treatment dropout 3

Critical caveat: Methadone requires dispensing through designated opioid treatment programs for ongoing treatment, limiting accessibility compared to office-based buprenorphine 4

2. Buprenorphine Alone (Without Naloxone)

• If the combination product is unavailable, buprenorphine monotherapy (SUBUTEX) remains highly effective 5
• Similar efficacy profile to the combination product 5
• May have slightly higher diversion risk without naloxone component

3. Extended-Release Naltrexone

• Injectable formulation (380 mg IM every 4 weeks) 6
• Noninferior to buprenorphine-naloxone for maintaining abstinence 6
• Significantly lower use of heroin and illicit opioids compared to buprenorphine-naloxone 6
• Major limitation: Requires complete detoxification first (7-10 days opioid-free), making initiation challenging for active users
• Lower risk of diversion or misuse 2

Symptomatic Management for Withdrawal (If Medication-Assisted Treatment Unavailable)

When opioid agonist therapy is completely unavailable, symptomatic treatment is substantially less effective but can provide temporary relief 1:

α2-Adrenergic Agonists (Most Effective Non-Opioid Option)

• Clonidine or lofexidine (FDA-approved 2018) 1
• Reduces withdrawal severity but less effective than buprenorphine or methadone 1
• Patients have more severe withdrawal symptoms and higher dropout rates compared to opioid agonist treatment 1

Adjunctive Symptomatic Medications

• Antiemetics (promethazine) for nausea/vomiting 1
• Benzodiazepines for anxiety and muscle cramps 1
• Loperamide for diarrhea 1

Critical warning: This approach has significantly worse outcomes than medication-assisted treatment and should only be temporary 3

Key Clinical Decision Points

For patients declining formal treatment programs:

1. First choice: Attempt to facilitate methadone access through opioid treatment programs—evidence shows this saves lives 2
2. Second choice: Extended-release naltrexone IF patient can complete detoxification 6
3. Last resort: Symptomatic management with clonidine/lofexidine while continuing to engage patient toward medication-assisted treatment 1

Abstinence-based treatment alone is substantially inferior to any medication-assisted treatment and should not be recommended as equivalent 3

Essential Harm Reduction Measures (Regardless of Treatment Choice)

• Naloxone prescription for overdose prevention (take-home kit) 1, 2
• Overdose prevention education 1
• Hepatitis C and HIV screening 1
• Reproductive health counseling 1

Bottom line: Methadone remains the gold standard alternative when buprenorphine products are unavailable, with the caveat that both are vastly superior to abstinence-only approaches for reducing mortality and improving quality of life 2, 3.